Alphyn Biologics recently announced results from the first cohort of its Phase 2a clinical trial of AB-101a in treating atopic dermatitis.
Almirall’s study shows tildrakizumab (Ilumetri®) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis.
The FDA has approved cantharidin (YCANTH™) for the treatment of molluscum contagiosum in pediatric and adult patients.
The clinical trial of ritlecitinib reports the drug demonstrated efficacy, improvement, and an acceptable safety profile.
Incyte announces positive results from its trial evaluating the safety and efficacy of ruxolitinib cream in pediatric patients with AD.
Data from Boehringer Ingelheim’s Effisayil 2 reveal that spesolimab significantly reduced the risk for generalized pustular psoriasis flares.
Galderma’s Olympia 2 study evaluating the safety and efficacy of nemolizumab in patients with prurigo nodularis shows positive results.
UNION therapeutics has announced positive topline results from its study of oral orismilast in adult patients with hidradenitis suppurativa.
Researchers have developed a breakthrough method enabling the early detection of infant atopic dermatitis known as ‘RNA monitoring’.
The FDA has cleared Candela’s Vbeam 595 nm Pulsed Dye Laser to treat port wine stains and hemangiomas in pediatric patients.
The FDA has approved ritlecitinib (LITFULO™) for patients aged 12 years and above with severe alopecia areata.
A recent study evaluated how REVIVV®could help patients with androgenetic alopecia improve their quality of life and emotional wellbeing.
A study evaluating the efficacy of diacerein 1% for epidermolysis bullosa simplex revealed it did not outperform vehicle in study endpoints.
New study maps the hidden features of inflammation in psoriatic disease, explaining the drivers behind disease severity.
Results of a Phase 3 clinical trial of guselkumab shows improvement in all minimal disease activity in adults with psoriatic arthritis.
A recent study of four patients with disabling pansclerotic morphea has revealed they share an overactive version of a protein called STAT4.
The European Commission has approved Novartis’ secukinumab (Cosentyx®) for the treatment of hidradenitis suppurativa (HS) in adults.
The FDA has approved Galderma’s Restylane Eyelight for the treatment of undereye hollows in adults aged 21 years and over.
Allergan Aesthetics, an AbbVie company, has announced that the FDA has approved their SKINVIVE™ by JUVÉDERM®.
Dermavant announces positive results from their ADORING 1 study evaluating the efficacy and safety of topical VTAMA® (tapinarof) cream, 1%.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
LiVDerm / South Beach Symposium
1801 N Military Trail, Ste 110
Boca Raton, FL, 33431
Copyright © 2025, LiVDerm. All Rights Reserved.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
